Little biotech makes deep cuts as it struggles to get narcolepsy drug approved amid months of regulatory limbo

Beleaguered by multiple delays, Avadel Pharmaceuticals is pulling out all the stops to try and clinch an FDA approval for its narcolepsy drug faster. But before it can get there, it is cutting its headcount by half.